ABT – Abbott Laboratories

Investment Analysis Report: Abbott Laboratories (ABT) – December 9, 2025

Company Overview

Abbott Laboratories, established in 1888 and headquartered in North Chicago, Illinois, stands as a global leader in the healthcare sector, with a strong focus on medical devices. Engaged in the discovery, development, manufacturing, and sale of an extensive range of healthcare products, Abbott operates through four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The company’s diverse portfolio includes generic pharmaceuticals for various medical conditions, advanced diagnostic laboratory systems, nutritional supplements for all ages, and innovative devices designed for chronic conditions like cardiac care and diabetes management. Positioned robustly within the healthcare sector, Abbott Laboratories is well-equipped to meet the increasing global demand for medical technology, making it a compelling investment opportunity.

52-Week Price Performance Analysis

Over the past year, Abbott Laboratories (NYSE: ABT) has experienced a variety of price fluctuations. Currently trading at $121.76, the stock is positioned noticeably below its 52-week high of $141.23 and close to the 52-week low of $110.86. This relative positioning suggests that ABBT may be undervalued, particularly since the stock’s price is nearing the lower end of its historical range.

The stock has exhibited a predominantly sideways trend throughout 2025, interspersed with periods of volatility. Notably, between December 2024 and February 2025, the stock surged to approximately $140 before entering a consolidation phase. Technical analysis indicates significant resistance near $135 and support levels located around $120 and $125.

The fifty-day moving average currently sits at $128.40, and Abbott’s stock trading below this average hints at bearish sentiment that could lead to further downward pressure. Recent price action shows a dip to around $122.09 — a critical support level which, if breached, may trigger declines further towards the $115 mark. Given these observations, investors should closely watch for consolidations or reversal patterns that could indicate a turning point in stock momentum.

Financial Performance and Metrics

Abbott Laboratories has posted impressive financial metrics that affirm its status as a cornerstone company within healthcare. The company reported total revenues of $43.84 billion, complemented by an EBITDA of about $11.75 billion, illustrating strong operational profitability.

Key Financial Metrics:

• Current Stock Price: $121.76
• Shares Outstanding: 1,738,871,947
• Short Shares: 19,141,411 (0.0111% of the float)
• Target High Price: $162.00
• Target Mean Price: $144.43
• Earnings Per Share (EPS): $1.26 (Q2 2025)

Despite these solid financials, the company faced a minor setback post-earnings announcement where a failure to revise full-year guidance led to an 8.1% decline in stock price. Nevertheless, the average analyst’s recommendation stands at a 1.71, indicating a “buy” sentiment, supported by a collective of 25 analysts.

Recent News and Developments

Recent developments surrounding Abbott Laboratories may impact investor sentiment and share performance:

1. Sensor Correction: Abbott has proactively addressed a manufacturing error concerning its FreeStyle Libre 3 glucose monitoring sensors. A health risk due to falsely low glucose reading impacts approximately 3 million devices, prompting the company to issue free replacements for affected users (Source).

2. Retail Expansion: In a strategic move, Walmart has become the first U.S. retailer to offer Abbott’s over-the-counter continuous glucose monitor, Lingo, expanding its market reach significantly. This initiative underscores the growing demand for non-invasive health monitoring solutions and positions Abbott favorably amid increasing public awareness of diabetes (Source).

These developments, while seemingly challenging, may play a crucial role in shaping future consumer trust and brand loyalty.

Market Sentiment and Analyst Recommendations

The prevailing market sentiment for Abbott Laboratories leans towards positivity, bolstered by its robust financial performance and an overall favorable outlook.

• Current Stock Price: $121.76
• Mean Target Price: $144.43
• Analyst Consensus: Buy (Recommendation key: 1.71)
• Median Target Price: $145.00
• Potential Upside: Approx. 18.53% towards the consensus mean

While the overall sentiment is optimistic, it is essential to consider the risks posed by recent operational issues and guidance stagnation. The relatively low percentage of short selling (0.0111%) reflects investor confidence, but the recent decline in share price–indicating a 7.71% drop–demands vigilant monitoring moving forward.

Conclusion

Abbott Laboratories presents a compelling investment opportunity, characterized by promising financials, an experienced operational trajectory, and an aggressive growth strategy encompassing recent market expansions and product corrections. Investors should remain attentive to potential volatility around key price levels and company developments. The opportunity for strong returns in the medical devices sector, combined with Abbott’s resilience and continued innovation, marks it as a potentially strategic addition to growth-oriented portfolios.

With the current stock price at $121.76, an investor can identify advantageous entry points, particularly if the stock maneuvers around critical support and resistance levels. As always, prudent decision-making and up-to-date market awareness are essential for navigating this ever-evolving landscape.

Metric	Value
Market Cap	$211.9b
Total Debt	$13.0b
Total Cash	$7.7b
Shares Outstanding	1.7b
Float Shares	1.7b